Bevacizumab Fails to Improve Survival in Resected High-Risk Melanoma

Treatment with single-agent bevacizumab resulted in an improved disease-free interval in patients with resected melanoma, but no increase in overall survival compared with observation.

Source: CancerNetwork - June 25, 2017 Category: Cancer & Oncology Authors: Leah Lawrence Tags: Melanoma News Source Type: news